# MARKET_RESEARCH_LOG_2026-08-26

> Production V3.1 hourly scan handoff. Repository `main` remains the source of truth. This log records completed production artifacts and is not an automatic trading instruction.

## Prior runs retained

01:10, 03:06 and 06:09 CST scans all concluded Formal BUY = NONE. `603658 安图生物` was the only execution-eligible durable deep-research candidate; `688526 科前生物` and `688687 凯因科技` were research-only. At 05:06, verified 2026H1 evidence downgraded the fundamental case for 603658: revenue ~flat, attributable profit -12.94% YoY, operating cash flow -47.38% YoY.

---

## 2026-08-26 07:08 CST — hourly production scan

### Canonical rules / provenance

- Latest `main` durable rules/handoffs were used; fresh-data invariant remains mandatory.
- Latest completed `GenGe V3.1 Every-Industry Research`: **success**, `run_id=32907982933`, run #83.
- Latest completed `GenGe Postscan Research Pipeline`: **success**, `run_id=32907982947`, run #511.
- Latest verified A-share trading day remains **2026-08-25** (pre-open on 2026-08-26); no newer legitimate price exists yet.
- Execution universe remains Shanghai/Shenzhen ordinary A shares only for actual-buy candidacy.

### Latest production result

- Long-term second pass remains 3 names: `603658 安图生物`, `688526 科前生物`, `688687 凯因科技`.
- `603658` remains the only execution-eligible durable candidate.
- Production artifact verifies `603658` close **34.17 CNY** on **2026-08-25**; observed entry band remains **33.58–34.15**.
- Frozen V3.1 review still marks it research-required / not A-eligible / not buy-ready. Unresolved hard-gate work includes predictability, long-term demand, moat, financial safety and normalized/scenario valuation evidence.
- The previously verified negative H1 evidence remains controlling: profit and cash-flow deterioration prevents promotion merely because price is near an observed entry band.
- `688526` and `688687` remain research-only and cannot enter the user's actual-buy queue.

### Ledger delta

- **NEW:** none.
- **RESEEN:** `603658 安图生物`.
- **UPGRADED:** none.
- **DOWNGRADED:** none this round; prior H1 evidence downgrade remains effective.
- **INVALIDATED:** none.
- **PRICE_ONLY_CHANGE:** none.

### Tier / Formal BUY

- **A1:** 0 new executable names.
- **A2:** 0 new executable names.
- **WATCH:** no new important execution-eligible queue addition.
- **WAIT:** `603658 安图生物`.
- **INVALIDATED:** none.
- **Formal BUY:** **NONE**.

### Production health / reproducibility

Both latest production workflows completed successfully. No data-source/CI failure or threshold relaxation was observed. Reproduction anchors: Every-Industry `32907982933`, Postscan `32907982947`, latest verified trade date `2026-08-25`, verified `603658` close `34.17`.

---

## 2026-08-26 12:08 CST — opportunity + holdings-risk production scan

### Canonical rules / provenance

- Re-read latest `main` `AGENTS.md`, V3.1 research handoffs/rules, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, `V31_CANDIDATE_LEDGER.md`, `CURRENT_HOLDINGS.md` and this daily log before assessment.
- Confirmed holdings source of truth remains the 2026-08-25 broker-evidence snapshot: `603369 今世缘` 300 @ 29.5003, `001316 润贝航科` 200 @ 26.0955, `600276 恒瑞医药` 100 @ 46.4115, `600406 国电南瑞` 200 @ 23.1258.
- Fresh-data invariant is binding. Public web retrieval during the midday scan did not provide a consistently independently verifiable 2026-08-26 intraday quote for the candidate/holding set. Therefore no intraday price is used to create Formal BUY/ADD or valuation-driven REDUCE.
- Latest trustworthy close evidence used where available remains 2026-08-25. Action conclusions below are fundamentals/thesis risk assessments, not cost-basis reactions.
- Recent GitHub Actions activity includes expected downstream `skipped` workflow-run events caused by repository/bot commits; no evidence of a production-chain failure that invalidates the scan was found.

### Candidate opportunity scan

- `603658 安图生物` remains **WAIT / Formal BUY = NO** and remains the only execution-eligible name in `CURRENT DEEP RESEARCH QUEUE`.
- Latest independently verified production price remains **34.17 CNY on 2026-08-25**, versus observed entry band 33.58–34.15. No 2026-08-26 intraday quote passed the fresh-data invariant in this run.
- Previously verified 2026H1 deterioration remains controlling: revenue about flat, attributable profit -12.94% YoY and operating cash flow -47.38% YoY. A near-entry-band price cannot override incomplete hard gates or weakening earnings quality.
- No new A1/A2 execution-eligible name was established; no candidate was promoted into an executable buy zone.
- Research-only `688526 科前生物` / `688687 凯因科技` remain outside the actual trading queue.

### Holding risk scan

#### 603369 今世缘 — HOLD / REVIEW, no REDUCE/EXIT trigger established

- 2026H1 revenue **64.35bn? corrected unit: 64.35 亿 RMB**, -7.41% YoY; attributable profit **20.82 亿**, -6.60%; deduct-profit **20.96 亿**, -5.77%.
- Operating cash flow **16.16 亿**, +50.31%, and Q2 revenue/profit improved YoY versus the weak Q1 base, so the current evidence is mixed rather than a clean multi-period thesis failure.
- Structural white-liquor demand is a V3.1 risk area and premium product revenue weakened, but this run did not recover repository evidence strong enough to formally mark the long-term-demand hard gate FAIL. Therefore no forced EXIT is declared merely from sector concern or the position being below cost.
- **REDUCE/EXIT trigger to watch:** continued multi-period volume/price contraction plus declining cash conversion/contract liabilities, material deterioration of provincial franchise strength, or a completed V3.1 hard-gate audit marking long-term demand/moat FAIL.
- **Current action:** HOLD_REVIEW; do not ADD until long-term-demand and normalized-earnings valuation are re-underwritten.

#### 001316 润贝航科 — HOLD, no REDUCE/EXIT trigger

- Verified 2026H1 revenue **5.73 亿**, +21.97%; attributable profit **1.12 亿**, +44.82%; deduct-profit +45.14%; operating cash flow **1.19 亿**, +26.52%.
- Self-developed/self-produced aviation-material revenue grew **35.78%** YoY. Current evidence supports rather than falsifies the localization/aviation-material thesis.
- 2026-08-25 close evidence recovered at roughly **26.23–26.74 CNY** depending public table revision; because the public page presented conflicting duplicate rows, this run does not treat it as a fresh executable price.
- **REDUCE/EXIT trigger to watch:** self-produced material growth stalls for multiple periods, cash conversion materially breaks, major airline/customer qualification loss, or product substitution/competition erodes the localization moat.
- **Current action:** HOLD; no ADD generated without a clean fresh price + updated valuation.

#### 600276 恒瑞医药 — HOLD_REVIEW, earnings-quality risk increased but no hard-logic EXIT

- Verified 2026H1 revenue **154.56 亿**, -1.94%; attributable profit **44.65 亿**, +0.34%; deduct-profit **37.30 亿**, -12.71%; operating cash flow **19.87 亿**, -53.8%.
- Q2 was weaker: revenue -14.49%, attributable profit -15.26%, deduct-profit -35.38% YoY. This is a material earnings-quality warning and must stay on the risk list.
- Offset: innovation-drug sales were **88.09 亿**, +16.38%, with non-oncology innovation revenue growing strongly; the innovation pipeline/portfolio thesis is therefore not yet falsified by the headline slowdown.
- Latest recovered reliable close is **46.49 CNY on 2026-08-25**.
- **REDUCE trigger to watch:** another reporting period of material deduct-profit + cash-flow deterioration without identifiable timing/base effects, innovation-drug growth slowing toward/under total market growth, or valuation/expectation-gap review showing price requires growth above supportable pipeline economics.
- **EXIT trigger:** evidence of durable pipeline/moat break, material regulatory/governance impairment, or frozen V3.1 hard-gate FAIL.
- **Current action:** HOLD_REVIEW; no REDUCE/EXIT yet because innovation demand/moat remains intact, but financial-quality confidence is lower.

#### 600406 国电南瑞 — HOLD, no REDUCE/EXIT trigger established

- Long-term grid digitization/UHV/power-system automation demand and grid-control/customer-certification moat remain the controlling thesis; no material current filing/event was found in this run that falsifies them.
- The run did not obtain a sufficiently fresh 2026H1 operating dataset/current intraday quote to support valuation-driven ADD/REDUCE. Missing evidence is treated as UNKNOWN, not PASS and not fabricated.
- **REDUCE/EXIT trigger to watch:** multi-period order/profit/cash-flow deterioration, material loss of grid-control share/qualification, structural capex reversal, or completed valuation showing price materially above Bull with negative expectation gap.
- **Current action:** HOLD; no ADD/REDUCE generated from incomplete current valuation evidence.

### Holding-risk delta

- **NEW REDUCE:** none.
- **NEW EXIT:** none.
- **RISK INCREASE:** `600276 恒瑞医药` — H1 deduct-profit and operating-cash-flow deterioration; action remains HOLD_REVIEW pending another period / normalized valuation and expectation-gap audit.
- **RISK WATCH:** `603369 今世缘` — structural demand question remains unresolved; H1 headline decline partially offset by stronger cash flow/Q2 recovery, so no hard-gate FAIL declared.
- **THESIS SUPPORTED:** `001316 润贝航科` — H1 earnings/cash flow/self-produced aviation-material growth all positive.
- **NO MATERIAL THESIS CHANGE:** `600406 国电南瑞` with current evidence available.

### Ledger delta

- **NEW:** none.
- **RESEEN:** `603658 安图生物` (last_seen -> 12:08 CST; seen_count -> 6).
- **UPGRADED:** none.
- **DOWNGRADED:** none this round; prior 安图 H1 evidence downgrade remains effective.
- **INVALIDATED:** none.
- **PRICE_ONLY_CHANGE:** none, because no independently verified 2026-08-26 intraday candidate quote was accepted.

### Tier / Formal BUY

- **A1:** no new executable entry.
- **A2:** no new executable entry.
- **WATCH:** no important new executable deep-research queue addition.
- **WAIT:** `603658 安图生物`.
- **INVALIDATED:** none.
- **Formal BUY / ADD:** **NONE**.

### Notification decision

No user-notification trigger is met this round: no new A1/A2 in executable buy zone, no important queue addition, no material candidate valuation/buy-band change, no holding with an established REDUCE/EXIT or hard-logic falsification, and no scan-invalidating production failure. Ordinary HOLD_REVIEW risk notes are persisted here for the next run.
